FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2743673880> ?p ?o ?g. }

• W2743673880 endingPage "1201" @default.
• W2743673880 startingPage "1191" @default.
• W2743673880 abstract "BACKGROUND: The clinical trial ARISTOTLE showed that apixaban was superior to warfarin in reducing the risks of stroke and bleeding among patients with nonvalvular atrial fibrillation (NVAF). Further study of the effect of apixaban versus warfarin use on health care resource utilization (HCRU) and associated costs in the real-world setting is warranted, especially among elderly patients who are at higher risk of stroke and bleeding. OBJECTIVE: To compare HCRU and costs among elderly NVAF patients treated with apixaban versus warfarin in the United States. METHODS: Elderly patients (aged ≥ 65 years) with Medicare coverage who initiated apixaban or warfarin were identified from the Humana research database during January 1, 2013-September 30, 2015. Patients were required to have 12 months of continuous insurance coverage before drug initiation (baseline period) and an atrial fibrillation diagnosis during the baseline period or on the date of drug initiation. NVAF patients were grouped into cohorts depending on the drug initiated. Propensity score matching (PSM) was conducted to control for differences in demographics and clinical characteristics of study cohorts. Patients were followed after the index date for a variable length of follow-up. All-cause and disease-specific HCRU and costs during the follow-up were evaluated before and after PSM and reported as per patient per year. RESULTS: Of the overall (unmatched) population, 8,250 patients (mean age: 78.0 years) initiated apixaban and 14,051 patients (mean age: 78.2 years) initiated warfarin. Among NVAF patients who initiated apixaban versus those who initiated warfarin, mean Charlson Comorbidity Index (CCI) scores (3.0 vs. 3.4, P < 0.001); stroke risk scores, including CHADS2 (2.7 vs. 2.9, P < 0.001) and CHA2DS2-VASc (4.6 vs. 4.7, P < 0.001); and bleeding risk scores, including HAS-BLED (3.1 vs. 3.2, P < 0.001), were lower. Additionally, total annual all-cause health care costs were lower during the baseline period for patients treated with apixaban versus warfarin ($17,077 vs. $20,236, P < 0.001). After PSM, 14,214 patients were matched, with 7,107 in each cohort. Mean age, CCI score, and stroke and bleeding risks were similar between matched cohorts, as were total all-cause health care costs during the baseline period. During the follow-up among matched cohorts, apixaban versus warfarin treatment was associated with higher annual pharmacy costs ($5,159 vs. $2,867, P < 0.001) but lower annual inpatient ($8,327 vs. $14,296, P < 0.001), outpatient ($9,655 vs. $11,469, P < 0.001), and total all-cause health care costs ($23,141 vs. $28,633, P < 0.001), which were reflective of lower inpatient, outpatient, and all-cause HCRU among apixaban-treated patients. Furthermore, bleeding-related ($2,101 vs. $3,963, P < 0.001) and stroke-related ($652 vs. $1,178, P = 0.001) annual medical costs were lower for patients treated with apixaban versus warfarin. CONCLUSIONS: After controlling for differences in patient characteristics, in the real-world setting apixaban versus warfarin use was associated with less HCRU and lower total all-cause health care costs and costs for bleeding- and stroke-related medical services, but greater pharmacy costs, among elderly NVAF patients. DISCLOSURES: This study was sponsored by Pfizer and Bristol-Myers Squibb. Deitelzweig is a consultant for Pfizer and Bristol-Myers Squibb and has served on their advisory boards and received speaker fees. Deitelzweig also serves as consultant and advisory board member to Portola and Janssen. Luo, Trocio, and Mardekian are employees of Pfizer and own stock in the company. Gupta and Curtice are employees of Bristol-Myers Squibb and own stock in the company. Lingohr-Smith, Menges, and Lin are employees of Novosys Health, which received research funds from Pfizer and Bristol-Myers Squibb to conduct this study and develop the manuscript. Study concept and design were primarily contributed by Deitelzweig, Luo, and Gupta, along with Trocio, Mardekian, Curtice, and Lin. Lin, Menges, and Lingohr-Smith took the lead in data collection, with assistance from the other authors. Data interpretation was performed by Deitelzweig, Menges, and Lin, with assistance from the other authors. The manuscript was written by Lingohr-Smith and Menges, along with the other authors, and revised by all the authors. Some aspects of this study were presented at the American Heart Association Scientific Sessions in New Orleans, Louisiana, November 12-16, 2016." @default.
• W2743673880 created "2017-08-17" @default.
• W2743673880 creator A5011447524 @default.
• W2743673880 creator A5026378192 @default.
• W2743673880 creator A5044665603 @default.
• W2743673880 creator A5050220227 @default.
• W2743673880 creator A5054571533 @default.
• W2743673880 creator A5057946660 @default.
• W2743673880 creator A5064854156 @default.
• W2743673880 creator A5076666408 @default.
• W2743673880 creator A5080303082 @default.
• W2743673880 date "2017-11-01" @default.
• W2743673880 modified "2023-09-26" @default.
• W2743673880 title "Effect of Apixaban Versus Warfarin Use on Health Care Resource Utilization and Costs Among Elderly Patients with Nonvalvular Atrial Fibrillation" @default.
• W2743673880 cites W1505468371 @default.
• W2743673880 cites W1990680911 @default.
• W2743673880 cites W2011188945 @default.
• W2743673880 cites W2013920814 @default.
• W2743673880 cites W2022095549 @default.
• W2743673880 cites W2025748852 @default.
• W2743673880 cites W2037850256 @default.
• W2743673880 cites W2051866975 @default.
• W2743673880 cites W2057773101 @default.
• W2743673880 cites W2061326496 @default.
• W2743673880 cites W2074119210 @default.
• W2743673880 cites W2074334843 @default.
• W2743673880 cites W2080507110 @default.
• W2743673880 cites W2126190086 @default.
• W2743673880 cites W2127985968 @default.
• W2743673880 cites W2132505348 @default.
• W2743673880 cites W2141889414 @default.
• W2743673880 cites W2155779925 @default.
• W2743673880 cites W2160161999 @default.
• W2743673880 cites W2162508946 @default.
• W2743673880 cites W2162586165 @default.
• W2743673880 cites W2164493375 @default.
• W2743673880 cites W2329586346 @default.
• W2743673880 cites W2433454023 @default.
• W2743673880 cites W2588488209 @default.
• W2743673880 cites W3190351271 @default.
• W2743673880 doi "https://doi.org/10.18553/jmcp.2017.17060" @default.
• W2743673880 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29083968" @default.
• W2743673880 hasPublicationYear "2017" @default.
• W2743673880 type Work @default.
• W2743673880 sameAs 2743673880 @default.
• W2743673880 citedByCount "14" @default.
• W2743673880 countsByYear W27436738802018 @default.
• W2743673880 countsByYear W27436738802019 @default.
• W2743673880 countsByYear W27436738802020 @default.
• W2743673880 countsByYear W27436738802022 @default.
• W2743673880 crossrefType "journal-article" @default.
• W2743673880 hasAuthorship W2743673880A5011447524 @default.
• W2743673880 hasAuthorship W2743673880A5026378192 @default.
• W2743673880 hasAuthorship W2743673880A5044665603 @default.
• W2743673880 hasAuthorship W2743673880A5050220227 @default.
• W2743673880 hasAuthorship W2743673880A5054571533 @default.
• W2743673880 hasAuthorship W2743673880A5057946660 @default.
• W2743673880 hasAuthorship W2743673880A5064854156 @default.
• W2743673880 hasAuthorship W2743673880A5076666408 @default.
• W2743673880 hasAuthorship W2743673880A5080303082 @default.
• W2743673880 hasBestOaLocation W27436738801 @default.
• W2743673880 hasConcept C126322002 @default.
• W2743673880 hasConcept C127413603 @default.
• W2743673880 hasConcept C167135981 @default.
• W2743673880 hasConcept C168563851 @default.
• W2743673880 hasConcept C177713679 @default.
• W2743673880 hasConcept C17923572 @default.
• W2743673880 hasConcept C194828623 @default.
• W2743673880 hasConcept C2776301958 @default.
• W2743673880 hasConcept C2778661090 @default.
• W2743673880 hasConcept C2779161974 @default.
• W2743673880 hasConcept C2780638905 @default.
• W2743673880 hasConcept C2780645631 @default.
• W2743673880 hasConcept C2908647359 @default.
• W2743673880 hasConcept C71924100 @default.
• W2743673880 hasConcept C78519656 @default.
• W2743673880 hasConcept C99454951 @default.
• W2743673880 hasConceptScore W2743673880C126322002 @default.
• W2743673880 hasConceptScore W2743673880C127413603 @default.
• W2743673880 hasConceptScore W2743673880C167135981 @default.
• W2743673880 hasConceptScore W2743673880C168563851 @default.
• W2743673880 hasConceptScore W2743673880C177713679 @default.
• W2743673880 hasConceptScore W2743673880C17923572 @default.
• W2743673880 hasConceptScore W2743673880C194828623 @default.
• W2743673880 hasConceptScore W2743673880C2776301958 @default.
• W2743673880 hasConceptScore W2743673880C2778661090 @default.
• W2743673880 hasConceptScore W2743673880C2779161974 @default.
• W2743673880 hasConceptScore W2743673880C2780638905 @default.
• W2743673880 hasConceptScore W2743673880C2780645631 @default.
• W2743673880 hasConceptScore W2743673880C2908647359 @default.
• W2743673880 hasConceptScore W2743673880C71924100 @default.
• W2743673880 hasConceptScore W2743673880C78519656 @default.
• W2743673880 hasConceptScore W2743673880C99454951 @default.
• W2743673880 hasIssue "11" @default.
• W2743673880 hasLocation W27436738801 @default.
• W2743673880 hasLocation W27436738802 @default.
• W2743673880 hasLocation W27436738803 @default.
• W2743673880 hasOpenAccess W2743673880 @default.

• next